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Abstract Therapy options at the time of recurrence of
glioblastoma multiforme are often limited. We investigated
whether treatment with a new intratumoral thermotherapy
procedure using magnetic nanoparticles improves survival
outcome. In a single-arm study in two centers, 66 patients
(59 with recurrent glioblastoma) received neuronaviga-
tionally controlled intratumoral instillation of an aqueous
dispersion of iron-oxide (magnetite) nanoparticles and
subsequent heating of the particles in an alternating mag-
netic ﬁeld. Treatment was combined with fractionated ste-
reotactic radiotherapy. A median dose of 30 Gy using a
fractionation of 5 9 2 Gy/week was applied. The primary
study endpoint was overall survival following diagnosis of
ﬁrst tumor recurrence (OS-2), while the secondary endpoint
was overall survival after primary tumor diagnosis (OS-1).
Survival times were calculated using the Kaplan–Meier
method. Analyses were by intention to treat. The median
overall survival from diagnosis of the ﬁrst tumor recurrence
among the 59 patients with recurrent glioblastoma was
13.4 months (95% CI: 10.6–16.2 months). Median OS-1
was 23.2 months while the median time interval between
primary diagnosis and ﬁrst tumor recurrence was
8.0 months. Only tumor volume at study entry was signif-
icantly correlated with ensuing survival (P\0.01). No
other variables predicting longer survival could be deter-
mined. The side effects of the new therapeutic approach
were moderate, and no serious complications were
observed. Thermotherapy using magnetic nanoparticles in
conjunction with a reduced radiation dose is safe and
effective and leads to longer OS-2 compared to conven-
tional therapies in the treatment of recurrent glioblastoma.
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Introduction
For most patients with newly diagnosed glioblastoma
multiforme (GBM), tumor resection followed by postop-
erative radiotherapy combined with temozolomide has
become the standard of care [1, 2]. However, when the
tumor recurs, subsequent treatment becomes highly case-
speciﬁc, taking into account the treatment history along
with the size and location of the tumor. Not all patients are
eligible for every type of salvage therapy, but a subset of
patients may beneﬁt from maximal treatment efforts [3].
Surgical removal of the recurrent tumor should be con-
sidered in all patients [4]. Repeated resection of recurrent
GBM has shown improvement in progression-free survival
[5], though its general efﬁcacy and utility clearly depends
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Re-irradiation is possible in many patients [6–11], and the
use of stereotactic techniques in particular has resulted in an
increase in post-recurrence median survival to 8–10 months
[12–14]. Nevertheless, there is still no general agreement on
which radiation technique and fractionation is most appro-
priate, and the choice often seems to depend upon the
radiotherapy options available to the treating physician.
Chemotherapy is the most common treatment option for
recurrent glioblastoma, and numerous studies have dem-
onstrated the safety and efﬁcacy of various agents, both
alone and in combination [15–19].
In addition to these standard therapies, alternative ther-
apeutic approaches have to some extent produced promis-
ing results or are the subject of ongoing investigations
[20–25]. The need for more efﬁcacious treatment options,
however, remains great. One of these, hyperthermia, has
already demonstrated efﬁcacy speciﬁcally in the treatment
of glioblastoma [26], but the high surgical effort required
to implant catheter arrays within the tumor along with the
non-negligible patient morbidity have hindered its estab-
lishment in clinical practice.
The combination of hyperthermia with radiotherapy
increases cytotoxic effects, and several clinical trials
investigating different techniques in different tumor sites
have shown beneﬁts from combined treatment [27–29]. In
our new approach, namely intratumoral thermotherapy
using magnetic nanoparticles (Nano-Cancer
 therapy),
biocompatible iron-oxide nanoparticles are directly injected
into the tumor and subsequently stimulated by an alternat-
ing magnetic ﬁeld to generate heat. The feasibility and
efﬁcacy of this approach were demonstrated in preclinical
[30, 31], clinical [32–34] and post-mortem studies [35].
The objective of the present study was to determine the
efﬁcacy of intratumoral thermotherapy in conjunction with
fractionated stereotactic radiotherapy for the treatment of
recurrent glioblastoma.
Methods
Study design and patients
This prospective, single-arm, two-center phase II study was
initiated in April 2005 and closed to accrual in September
2009. The study population consisted of 66 patients. Seven
of these did not fulﬁll the inclusion criteria, such that a total
of 59 patients (54% male) with recurrent glioblastoma were
included in the statistical analysis of overall survival.
The key criteria for eligibility were: histologic diagnosis
of supratentorial glioblastoma; unequivocal evidence of
recurrence or progression (as determined by the referring
physicians using MRI) with up to three additional foci;
maximum tumor dimension of 7 cm; absence of tumor
inﬁltration into the ventricle, brain stem, corpus callosum
or contralateral site; age between 18 and 75 years; Kar-
nofsky performance score (KPS) C 60; and a life expec-
tancy of at least 3 months. Irremovable metallic parts in the
treatment area, cardiac pacemaker and implanted deﬁbril-
lator were exclusion criteria. The study, approved by the
institutional review boards of the participating centers, was
conducted according to the principles of the Declaration of
Helsinki. All patients certiﬁed their fully informed consent.
Following the treatment procedure, patients were mon-
itored at 3-month intervals with follow-up clinical exam-
inations including CT scans. One patient was lost during
the follow-up period, and in this case survival was deemed
until the time of the last CT scan. Data on any subsequent
treatments for tumor progression following the thermo-/
radiotherapy were not systematically collected.
Magnetic ﬁeld applicator and magnetic ﬂuid
The thermotherapy was performed using the alternating
magnetic ﬁeld applicator MFH 300F with integrated ther-
mometry unit (NanoActivator
 F100; MagForce Nano-
technologies, Berlin, Germany). The strength of the
alternating (100 kHz) magnetic ﬁeld can be adjusted from
2 to 15 kA/m. The applicator is designed for universal
usage in treating tumors anywhere in the body.
The magnetic ﬂuid MFL AS1 (NanoTherm
 AS1;
MagForce Nanotechnologies), an aqueous dispersion of
superparamagnetic nanoparticles with an iron concentra-
tion of 112 mg/ml, served as the energy transducer. The
nanoparticles are formed as iron-oxide magnetite (Fe3O4)
cores of approx. 12 nm diameter with an aminosilane
coating, which acts to ensure that the nanoparticle deposits
remain stable within the tumor tissue. The magnetite cores
possess an intrinsic magnetic moment, which can be
stimulated by the externally applied alternating magnetic
ﬁeld to create heat through relaxation processes. The high
concentration of iron was necessary to generate sufﬁcient
heat within the tumor for effective thermotherapy, while
simultaneously minimizing the volume of instilled ﬂuid.
Instillation and thermotherapy
Prior to treatment, it was ﬁrst necessary to remove all
metallic materials within 40 cm of the treatment area,
particularly dental ﬁllings, crowns and implants.
The magnetic ﬂuid was instilled using neuronavigational
control under general anesthesia in a procedure comparable
to a brain needle biopsy. The median amount of magnetic
ﬂuid injected was 4.5 ml (range 0.5–11.6 ml), corre-
sponding to a median dosage of 0.28 ml of magnetic ﬂuid
per cm
3 of tumor volume. Following instillation of the
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123magnetic ﬂuid, a closed-end thermometry catheter (outside
diameter 1.0 mm) was placed in the target area.
Thereafter, the nanoparticle density was mapped using
CT imaging so that the treatment parameters for the
subsequent intratumoral thermotherapy could be planned
(Fig. 1). On the basis of the density distribution of the
nanoparticles, their known speciﬁc absorption rate (SAR),
and the estimated perfusion within the tumor area, the heat
generation within the target tissue could be determined as a
function of magnetic ﬁeld strength using the bioheat
transfer equation. The aim was to establish the magnetic
ﬁeld strength such that a temperature of 43C was not
exceeded beyond a margin of 2 cm around the tumor.
Further details of this treatment planning process, referred
to as post-instillation analysis (PIA), have been described
by Gneveckow et al. [36].
The hyperthermia treatment generally consisted of six
semi-weekly sessions, and each thermotherapy session
lasted 1 h. During the ﬁrst two sessions,the procedure was
monitored using direct temperature measurements from the
previously placed thermometry catheter. Since the maxi-
mum ﬁeld strength of the remaining sessions did not
exceed that of the ﬁrst two sessions, these were performed
without direct temperature measurement. The median peak
temperature measured within the tumor area during the
thermotherapy sessions was 51.2C (maximum 82.0C).
Adjunct radiotherapy
Stereotactic beam radiotherapy was performed immediately
before or after the intratumoral thermotherapy sessions
with a 6 MV Novalis system (Varian, Palo Alto, USA/
Fig. 1 Glioblastoma recurrence. a,b Pre-treatment brain MRI.
c,d Post-instillation CT showing magnetic nanoparticle deposits as
hyperdense areas. Isothermal lines indicate calculated treatment
temperatures between 40C( blue) and 50C( red). The brown line
represents the tumor area. e,f 3-D reconstruction of fused MRI and
CT showing the tumor (brown), magnetic ﬂuid (blue) and thermom-
etry catheter (green)
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volume (PTV) enclosed the regions of contrast enhance-
ment including any resection cavity and an additional
margin of 3 mm. The median PTV was 46.5 cm
3 (range
6.6–108.0 cm
3). Treatment planning for radiotherapy
was done using Brainscan
 or iPlan
 software (BrainLAB,
Feldkirchen, Germany). A biologically equivalent median
dose (BED) of 30 Gy was administered in C95% of the
PTV, generally fractionated as 5 9 2 Gy per week.
Statistical analysis
Survival times were calculated using the Kaplan–Meier
method. The primary endpoint of the study was overall
survival following the ﬁrst diagnosis of tumor recurrence or
progression (OS-2). The secondary endpoint was overall
survival from the time point of primary diagnosis of glio-
blastoma (OS-1). Inﬂuence of prognostic factors on sur-
vival was evaluated using the logrank test and correlation
analysis was done using Pearson’s correlation coefﬁcient.
The software program used for the statistical analyses was
SPSS Statistics 18.
Results
Medianpatientageatstudyentrywas55.7 years.Atotalof41
patientshad previously received a complete and 15 a subtotal
tumor resection upon primary diagnosis. In 2 patients, only a
biopsy had been performed, and in 1 patient the extent of
resection could not be retraced. The median time interval
between diagnosis of primary glioblastoma and ﬁrst tumor
recurrence/progression (TTP-1) was 8.0 months. Further
details of the study population are listed in Table 1.
Over the study period ending 30 September 2009, 47 out
of the 59 patients with recurrent glioblastoma died. In only
41 of these was there no doubt that death was caused by
tumor growth. However, in order to be conservative, all 47
deaths were regarded as tumor-related.
Median OS-2 estimated using the Kaplan–Meier method
was 13.4 months (95% CI: 10.6–16.2 months) in the study
population (Fig. 2). In differentiating the study population
between those who had had prior treatment following the
ﬁrst tumor recurrence (n = 24, see Table 1) and those
who had not (n = 35), the median OS-2 for those who
had was 13.9 months (95% CI: 10.9–16.8), compared to
11.2 months (95% CI: 6.7–15.6) for those who had not.
Median OS-1 was 23.2 months with a 95% conﬁdence
interval of 17.2–29.2 months.
All standard prognostic factors were analyzed for their
impact on survival. Only tumor volume at study entry was
signiﬁcantly correlated with ensuing survival (log-rank test,
P\0.01). No other factors—age, KPS, TTP-1, or prior
treatment following ﬁrst recurrence—had any signiﬁcant
prognosticvalueonOS-2.OnlybetweenTTP-1andOS-1was
there a positive linear correlation which was signiﬁcantly
different from zero (r = 0.65; P\0.01). The Pearson’s
correlationcoefﬁcient(r)betweenTTP-1andOS-2,however,
was almost zero (no relationship). No correlations were
observed between tumor location, size or attained treatment
temperatures and either OS-2 or observed side effects.
Acute side effects during thermotherapy were classiﬁed
according to version 2.0 of the Common Toxicity Criteria
(CTC). The following side effects were observed in more
than one patient.
During thermotherapy sessions, 33 patients (50.0%)
exhibited sweating up to grade 1, and 31 (47.0%) reported
a general sensation of warmth in the treatment area. In 6
patients (9.1%), body temperature during thermotherapy
exceeded 38C (grade 1–3 thermal stress), while the body
Table 1 Patient characteristics (n = 59)
No. (%)
First-line therapy
Resection 56 95
Radiotherapy 58 98
Chemotherapy 51 86
Patients with prior treatment following
tumor recurrence but before study entry
24 41
Resection 11 19
Radiotherapy 2 3
Chemotherapy 17 29
KPS at study entry—median (range) 90 (60–100)
Karnofsky performance score (KPS) C80 46 78
Age in years at study entry—median 55.7
Patients with age\50 23 39
Patients with age C50 36 61
Fig. 2 Overall survival after diagnosis of ﬁrst tumor recurrence/
progression (OS-2) of 59 glioblastoma patients treated with combined
thermo-/radiotherapy for reintervention
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123temperature of all other patients increased only slightly
during the treatment procedure. No correlation could be
established between body temperature elevation and the
size or number of lesions being treated.
Twelve patients (18.2%) demonstrated grade 1 tachy-
cardia during the thermotherapy procedure. Short-term
ﬂuctuations in blood pressure not requiring treatment were
observed in 10 patients: hypertonia in 7 (10.6%), and
hypotonia in 3 (4.5%).
Nine patients (13.6%) reported headaches during thermo-
therapy. These were generally mild and temporary, but in 3
patients they led to individual thermotherapy sessions being
aborted. It is possible that they were caused by a transitory
increase in intracranial pressure resulting from the local
increaseintemperature.Fifteenpatients(22.7%)experienced
convulsions which were mostly focal. Anti-epileptic drugs
(AEDs) already being taken by patients were maintained.
While AEDs were not administered prophylactically prior to
commencement oftherapy inthisstudy,thisapproachshould
be considered in the future. Fourteen patients (21.2%)
exhibited motor disturbances, mostly as a worsening of
already existing hemiparesis. In 4 of these, the symptoms
appeared following the nanoparticle instillation procedure,
while in the others, motor disturbances were observed after a
varying number of thermotherapy sessions. By using CT
imaging, an enlargement of perifocal edema could be
observedin6ofthesepatients.However,only2(3.0%)ofthe
patients experiencing convulsions or motor disturbances
demonstrated such neurological disorders for the ﬁrst time.
Except for worsening of hemiparesis, no prolonged side
effects were observed. In 19 patients, key parameters of iron
metabolism (ferritin, transferrin, transferrin saturation, serum
iron) were tested both before and after the instillation of
magnetic ﬂuid, and there was no indication of iron being
releasedfromtheintratumoraldeposits orbeingmetabolized.
Discussion
The objective of the present single-arm study was to
demonstrate the clinical efﬁcacy of the newly developed
intratumoral thermotherapy using magnetic nanoparticles
in conjunction with percutaneous irradiation for the treat-
ment of recurrent GBM.
Because it is not randomized, this study speciﬁcally rec-
ognizes the potential for selection bias. A randomization
would have been possible in theory but extremely difﬁcult in
practice because patients with recurrent glioblastoma are
acutely aware of their impending mortality and therefore
typically make a highly considered decision about any par-
ticipationintrialsofanewexperimentaltherapy.Mostwould
beloathtoparticipateinarandomizedstudywheretheymight
only be receiving supportive treatment, and thus recruiting
patients for randomized trials would have been difﬁcult and
considerably extended the time required for this study.
As with many other carcinomas, pre-therapeutic prog-
nostic factors are major determinants of overall survival
[37, 38], and survival may show greater correlation to these
factors than any speciﬁc treatment. Selecting historical con-
trols from past studies is thus not unproblematic since these
frequently involve only small populations with differing
prognostic factors (particularly KPS, age and prior treat-
ment). For this reason, many studies have utilized the meta-
analysis by Wong et al. [39] as a baseline historical reference
population. According to their study, the median survival for
patients treated with chemotherapy following glioblastoma
recurrence was 5.8 months. However, the recently published
results ofthe EORTC-NCICtrialonprimaryglioblastoma by
Stupp etal. [1,2]reﬂectthemorerecentuseoftemozolomide
as the current standard in the treatment of primary glioblas-
toma, and thus its results establish, in principle, a new
baseline for survival data. Its OS-2 is particularly well suited
to direct comparison with future study results because the
primary therapy was conducted on a large patient population
(n = 287) using this currently prevailing standard treatment,
while upon recurrence/progression, patients were treated at
the local investigators’ discretion. The OS-2 data from this
study may therefore be viewed as broadly representative of
median survival using the range of salvage therapies cur-
rently available.
While recognizing the issues of data comparability
between our’s and other studies, the extension of median
OS-2 to 13.4 months in our study compared to 6.2 months
in the Stupp study population [2] can clearly be regarded as
signiﬁcant (using the statistical method of Simon [40]). It
should speciﬁcally be noted that it is not the results of the
primary therapy being compared but rather survival fol-
lowing the best possible treatment upon tumor recurrence
after standard ﬁrst-line treatment.
Further evidence suggesting superiority of this new
therapy is provided by the median secondary study end-
point OS-1, which at 23.2 months substantially exceeded
the median 14.6 months in the reference group [1]. In
comparing the increase in median OS-2 of 7.2 months to
the gain in OS-1 of 8.6 months, it is apparent that the great
majority of the gain in overall survival followed recurrence
and thus can be speciﬁcally attributed to the thermo-/
radiotherapy. If one restricts the study group to only those
patients who had not received any prior treatment follow-
ing their ﬁrst recurrence (n = 35), the median OS-2 for this
subset is shortened to 11.2 months but still much greater
than 6.2 months. It may thus be inferred that the observed
increase in survival is not attributable to any prior treat-
ment of the recurrence before study entry. The remaining
patients who had been previously treated (n = 24) had a
median OS-2 of 13.9 months.
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extremely close to the reference population (57 years), and
median TTP-1 differed only modestly (8.0 vs 6.9 months),
suggesting that the study results were not materially
affected by patient selection and thus that they are clini-
cally relevant. Data on other prognostic factors, such as
tumor volume and KPS at recurrence, were unfortunately
not available for the reference population.
In addition to examining the potential role of patient
selection on survival, the extent to which the adjunct
radiotherapy might have contributed to the increased sur-
vival must also be addressed. Prior studies of stereotactic
fractionated radiotherapy following GBM recurrence,
however, demonstrate only a lower increase in median
survival, and in small patient groups. Hudes et al. [8] and
Vordermark et al. [13] attained respective OS-2 of
10.5 months (n = 19) and 7.9 months (n = 14) using
hypofractionated stereotactic radiotherapy, but both these
studies involved relatively small tumor volumes. However,
a retrospective study by Combs et al. involving similar
tumor volumes in a comparable patient population (in
terms of KPS and age) found a median survival of
8.1 months following fractionated stereotactic re-irradia-
tion at a level of 36 Gy [12].
The remarkable increase in overall survival in our study
through the combination of thermotherapy with a lower
radiotherapy dosage of 30 Gy thus indicates the efﬁcacy of
the applied heat, at least in this combination. It must be
underscored that the studies of stereotactic radiosurgery
involving tumors of signiﬁcantly smaller volume do not
necessarily offer a valid basis of comparison with our study
results.
Even with deliberate selection of patients being treated
for recurrent GBM using predeﬁned criteria, Hau et al. [3]
could demonstrate only a modest increase in OS-2 to
7.6 months, although it must be noted that, with a median
KPS of 70 and a TPP-1 of 6 months, the prognosis for their
patient group was presumably slightly worse than for our
own study population.
With regard to safety, intratumoral thermotherapy offers
an approach to hyperthermia (or thermoablation) with only
moderate side effects.
Two drawbacks of this new approach which warrant
mention are, ﬁrstly, the need to remove all metal from
within 40 cm of the treatment area (i.e., all dental work),
and secondly, the indeﬁnite exclusion of MRI for sub-
sequent diagnosis of tumor progression. There remain,
however, other effective methods beside CT to monitor
disease progression including PET and SPECT, which can
be regarded at least as good as MRI. Outside the area of
nanoparticle deposits, conventional MRI according to
current practice may still be used without any limitation. It
should be noted that the exclusion of MRI for evaluating
tumor progression arises not from the effects of MRI on the
magnetic nanoparticles but, conversely, from the MRI
artifacts resulting from the very high particle concentra-
tions used. By comparison, iron-oxide nanoparticles are
used in much lower concentrations for therapeutic targeting
and MRI contrast enhancement of glioblastoma [41].
In looking at the entirety of the observed side effects,
intratumoralthermotherapymay beregardedassafe and well
tolerated compared to other available treatment options. This
study likewise demonstrates that, in the indicated patient
group, this new therapeutic approach in conjunction with
fractionated stereotactic radiotherapy is clinically effective.
The increase in overall survival points to a clearly favorable
risk–beneﬁt ratio in patients with recurrent GBM.
Intratumoral thermotherapy may, in principle, be used in
combination with any conventional therapy in order to
amplify its effects and thus offers the potential for even
greater potency. Because of the stability of the nanoparticle
deposits, and in contrast to radiotherapy, which is subject
to cumulative dosage limits, the thermotherapy sessions
may be repeated or combined with other therapies without
any inherent limit. The combination of intratumoral
hyperthermia and chemotherapy (particularly temozolo-
mide) presents a particularly promising approach which
warrants further clinical investigation. The delivery of
nanoparticles into the tumor using convection-enhanced
delivery (CED) might be a potential alternative to direct
intratumoral instillation and is thus also a potential subject
for examination in future clinical studies.
Furthermore, because there are only marginal differ-
ences in temperature sensitivity between different body
tissues [27], one may suppose that patients with other solid
tumors besides glioblastoma might beneﬁt from this novel
approach provided that sufﬁcient temperatures can be
safely attained in these tumors. This is the subject of other
clinical studies currently in progress.
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